Takeda To Start Phase I For Antibody Neuropathic Pain Drug
This article was originally published in PharmAsia News
Takeda Pharmaceutical subsidiary Takeda Bio plans to start a domestic Phase I trial for neuropathic pain antibody injection AMG403
You may also be interested in...
OTC Decisions In March: Lumify Single-Use, Aleve Arthritis-Grip Cap Labeling, And More Prilosec, Mucinex Copies
Total of CDER decisions during March on OTC applications was down from January and February and also were less substantial for the marketplace. After approving OTC switches in first two months, March decisions for newly available OTCs were limited to additional guaifenesin/pseudoephedrine and omeprazole products offered as private label/store brand alternatives to brands.
NPA asks Congress to include supplements in legislation defining "medical expenses” covered by pre-tax health savings accounts. The trade group says industry would prefer supplements were included with OTC drugs in provision in recently passed COVID-19 relief legislation that changed pre-tax account rules.
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.